Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 1
2005 4
2006 5
2007 1
2008 1
2010 1
2011 2
2012 1
2013 2
2014 5
2015 3
2016 11
2017 15
2018 18
2019 21
2020 18
Text availability
Article attribute
Article type
Publication date

Search Results

106 results
Results by year
Filters applied: . Clear all
Page 1
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Mahmood SS, et al. Among authors: heinzerling lm. J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19. J Am Coll Cardiol. 2018. PMID: 29567210 Free PMC article.
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.
Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R. Heinzerling L, et al. ESMO Open. 2019 May 23;4(3):e000491. doi: 10.1136/esmoopen-2019-000491. eCollection 2019. ESMO Open. 2019. PMID: 31231568 Free PMC article. Review.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Heinzerling L, et al. J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016. J Immunother Cancer. 2016. PMID: 27532025 Free PMC article.
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Hofmann L, et al. Among authors: heinzerling lm. Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13. Eur J Cancer. 2016. PMID: 27085692
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L. Moreira A, et al. Among authors: heinzerling l. Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17. Eur J Cancer. 2019. PMID: 30453170
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Zimmer L, et al. Among authors: heinzerling lm. Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13. Eur J Cancer. 2016. PMID: 27084345
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology.
Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Bonaca MP, et al. Among authors: heinzerling l. Circulation. 2019 Jul 2;140(2):80-91. doi: 10.1161/CIRCULATIONAHA.118.034497. Circulation. 2019. PMID: 31390169 Free PMC article. Review.
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Zimmer L, et al. Among authors: heinzerling l. Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214657 Clinical Trial.
Checkpoint Inhibitors.
Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Heinzerling L, et al. Dtsch Arztebl Int. 2019 Feb 22;116(8):119-126. doi: 10.3238/arztebl.2019.0119. Dtsch Arztebl Int. 2019. PMID: 30940340 Free PMC article. Review.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD. Weide B, et al. Among authors: heinzerling l. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185375 Free PMC article.
106 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback